Nektar Therapeutics (NKTR)
(Real Time Quote from BATS)
$0.89 USD
0.00 (0.55%)
Updated Mar 28, 2024 10:56 AM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Income Statements
Fiscal Year end for Nektar Therapeutics falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 90 | 92 | 102 | 153 | 115 |
Cost Of Goods | 34 | 22 | 25 | 19 | 21 |
Gross Profit | 56 | 70 | 77 | 133 | 93 |
Selling & Adminstrative & Depr. & Amort Expenses | 320 | 447 | 523 | 559 | 533 |
Income After Depreciation & Amortization | -264 | -376 | -446 | -425 | -440 |
Non-Operating Income | 13 | 40 | -30 | 18 | 46 |
Interest Expense | 25 | 29 | 47 | 37 | 46 |
Pretax Income | -276 | -365 | -523 | -444 | -440 |
Income Taxes | 0 | 3 | 1 | 0 | 1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -276 | -368 | -524 | -444 | -441 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -276 | -368 | -524 | -444 | -441 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -179 | -363 | -425 | -411 | -427 |
Depreciation & Amortization (Cash Flow) | 84 | 13 | 21 | 14 | 13 |
Income After Depreciation & Amortization | -264 | -376 | -446 | -425 | -440 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 190.00 | 187.14 | 183.30 | 178.58 | 174.99 |
Diluted EPS Before Non-Recurring Items | -0.86 | -1.97 | -2.86 | -2.24 | -2.52 |
Diluted Net EPS (GAAP) | -1.45 | -1.97 | -2.86 | -2.49 | -2.52 |
Fiscal Year end for Nektar Therapeutics falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 | |
---|---|---|---|---|---|
Sales | 23.89 | 24.14 | 20.50 | 21.59 | 22.02 |
Cost Of Goods | 7.28 | 12.43 | 6.99 | 7.06 | 6.23 |
Gross Profit | 16.60 | 11.71 | 13.51 | 14.53 | 15.79 |
SG&A, R&D, and Dept/Amort Expenses | 50.11 | 56.58 | 64.10 | 149.24 | 68.26 |
Income After SG&A, R&D, and Dept/Amort Expenses | -33.51 | -44.87 | -50.59 | -134.71 | -52.47 |
Non-Operating Income | 4.52 | 4.88 | 5.58 | 4.03 | 3.13 |
Interest Expense | 6.87 | 5.91 | 6.15 | 6.41 | 7.20 |
Pretax Income | -42.11 | -45.90 | -51.17 | -137.08 | -56.54 |
Income Taxes | -0.03 | -0.06 | -0.05 | -0.06 | 3.14 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -42.08 | -45.84 | -51.12 | -137.02 | -59.69 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -42.08 | -45.84 | -51.12 | -137.02 | -59.69 |
Earnings Per Share Data | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | 12/31/22 |
---|---|---|---|---|---|
Average Shares | 191.04 | 190.41 | 189.66 | 188.88 | 188.24 |
Diluted EPS Before Non-Recurring Items | -0.22 | -0.19 | -0.27 | -0.25 | -0.32 |
Diluted Net EPS (GAAP) | -0.21 | -0.24 | -0.27 | -0.73 | -0.32 |